Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

Article Details

Citation

Copy to clipboard

Briones M, Bajaj M

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus.

Expert Opin Pharmacother. 2006 Jun;7(8):1055-64.

PubMed ID

16722815 [ View in PubMed

]

Abstract

Exenatide is a glucagon-like peptide 1 receptor agonist, which has recently received FDA approval in the US for the treatment of Type 2 diabetes. Exenatide is an incretin mimetic that improves glycaemic control in patients with diabetes through acute mechanisms, such as glucose-dependent stimulation of insulin secretion, suppression of inappropriate glucagon secretion and slowing of gastric emptying, as well as chronic mechanisms that include enhancement of beta-cell mass in rodent studies and weight loss and inhibition of food intake in humans. This article reviews the mechanisms of exenatide action, as well as its efficacy in the treatment of Type 2 diabetes.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Exenatide	Glucagon-like peptide 1 receptor	Protein	Humans	Yes	Agonist	Details